Navigation Links
Charleston Conducts Evaluation of an Opioid Symptoms Questionnaire

CHARLESTON, S.C., Feb. 12 /PRNewswire/ -- Charleston Laboratories, Inc, an emerging specialty pharmaceutical company dedicated to reducing opioid-induced nausea and vomiting (OINV) in opioid pharmaceuticals, announced preliminary findings from its development and testing of an Opioid Symptoms Questionnaire, or OSQ, which will be used in Charleston's clinical trials.

"This pilot methodology study was designed to test the feasibility and reliability of the OSQ," reported Dr. Bernard Schachtel, Chief Scientific Officer at Charleston Labs. "All patients used the OSQ before and at intervals after ingesting different opioid drugs to indicate the presence and severity of symptoms caused by these medications.

"Using the OSQ prospectively, showing natural progression of opioid side effects," Dr. Schachtel continued, "patients detected different symptoms, not just nausea or vomiting, in good accordance with conventional methods, occasionally with better sensitivity. We will be presenting the final results from this version of the OSQ and other measurement instruments to our Scientific Advisory Board and the clinical investigators for their review and input before completing the protocol for our full-sized clinical trial."

This methodology study was conducted in preparation for Charleston's studies on patients who may experience OINV, the target indication for Charleston's first opioid drug, CL-108. Arrangements are being made with clinical investigators at major universities and research sites in the US to participate in a multi-centered double-blind, randomized, placebo-controlled, multiple-dose safety and efficacy study on over 1,000 patients with post-operative pain. The purpose of this Phase III study is to evaluate CL-108 for relief of acute moderately severe or severe pain and the reduction or elimination of OINV.

All clinical studies for Charleston Laboratories are being overseen by SRC, Inc., a contract research organization based in Jupiter, Florida, which specializes in clinical trials on patients' symptoms (such as nausea).

About Charleston Laboratories, Inc

Charleston Laboratories Inc, headquartered in Charleston, SC, is a privately funded specialty pharmaceutical company developing and commercializing opioid drugs with minimal or no opioid-induced nausea and vomiting (OINV). Charleston Laboratories intends to enter into discovery and commercialization alliances with partners motivated to introduce novel pain therapies that eliminate or significantly reduce nausea and vomiting.

SOURCE Charleston Laboratories, Inc
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Doug Flutie, Jr. Foundation Grants NAA $10,000 for Burbacher/Charleston Study
2. The Hope Clinic in Charleston, SC invests in technology to prevent vision loss in patients
3. Charleston, S.C., Market Integration Likely to Drive Physician Groups to Seek Health System Affiliation
4. Charleston Laboratories, Inc. Phase I Clinical Trial
5. Hospital Clínic conducts the first kidney extraction through the vagina in Europe
6. LCA-Vision Conducts 2008 Annual Stockholder Meeting
7. iCRco Conducts First Annual Asia Pacific Distributor Training Program
8. AARP Responds to Senator Grassley, Conducts Comprehensive Review of Marketing of Fixed Benefit Indemnity Products
9. Pennsylvania State Health Department Conducts Pertussis Immunization Clinic in Mercer County
10. NASA Conducts Pilot Cognition Studies
11. New data on hormone therapy must lead to re-evaluation of official guidelines
Post Your Comments:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: